TG Therapeutics, Inc. (TGTX) Stock Split, History Data
Working capital analysis
In terms of working capital, TG Therapeutics, Inc. maintains a healthy position.
The total current assets of the company are valued at $317943000.
This represents a growth rate of 88.944% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $92933000, exhibiting a growth rate of -9.160% year-on-year.
The receivables, another significant portion of the current assets, are valued at $51093000.
The inventory, which forms a critical part of the assets, is valued at $39823000.
On the liabilities side, the company's current liabilities total $53720000.
This reflects a growth rate of 0.976% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
92.93
102.30
298.89
553.44
112.64
41.96
Receavebles
51.09
0.00
1.39
0.00
0.00
0.10
Inventory
39.82
0.00
23.6
0.00
0.00
9.69
Other
9.52
6.60
2.88
1.08
0.61
0.44
Total Current Assets
317.94
168.27
330.96
611.74
149.15
79.03
Acc Payable
38.47
42.02
0.46
37.01
30.04
36.38
Short Term Debt
1.45
1.58
2.41
23.85
1.62
0.07
Other Current Liab
13.50
9.30
62.97
26.54
5.44
2.26
Current Liabilities
53.72
53.20
65.38
87.55
84.45
38.85
Capital Structure
When examining the capital structure of TG Therapeutics, Inc., it is clear that the company manages a robust portfolio.
The value of their total assets clocks in at $373323000.
When juxtaposed with the previous year, this marks a growth rate of 89.160%, showcasing the company's ability to steadily grow its asset base.
Compared to the prior year, this reflects a growth rate of -100.000%.
Over the last year, the long-term debt has grown by -100.000%.
On the asset side, the cash and equivalent reserves are worth $-217508000.
The year-on-year growth of these reserves is -453.850%.
Finally, the company's retained earnings stand at $1525068000, marking a growth rate of -197.370% year-over-year.
These earnings represent the profits that TG Therapeutics, Inc. has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$373.32
Total liabilities
$0.00
Long term debt
$0.00
Cash and eqv
-$217,508,000.00
Goodwill
$0.00
Retained earnings
$1,525,068,000.00
Common stock
$0.00
Enterprise Value
$46.44
Net earnings per share (EPS)
TG Therapeutics, Inc. has an EPS of $-0.07, which signifies the profit allocated per share of common stock. With a growth rate of -191.500% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
Years
Q1
Q2
Q3
Q4
Total
2024
-0.0732
-
-
-
-0.07
2023
-0.28
-0.34
0.8
-0.1
0.08
2022
-0.53
-0.31
-0.27
-0.39
-1.50
2021
-0.69
-0.59
-0.65
-0.7
-2.63
2020
-0.48
-0.47
-0.73
-0.71
-2.39
2019
-0.43
-0.42
-0.69
-0.41
-1.95
2018
-0.59
-0.61
-0.43
-0.68
-2.31
2017
-0.52
-0.45
-0.48
-0.46
-1.91
2016
-0.28
-0.33
-0.5
-0.48
-1.59
2015
-0.35
-0.38
-0.28
-0.37
-1.38
2014
-0.25
-0.36
-0.51
-0.48
-1.60
2013
-0.17
-0.29
-0.16
-0.19
-0.81
2012
-2.03
-0.16
-0.16
-0.17
-2.52
2011
83.04
-1.64
-0.21
-0.23
80.96
2010
-54.27
43.31
1.12
0.0263
-9.81
2009
-30.34
-55.45
-16.57
-0.0074
-102.37
2008
-62.1
-56.64
-55.53
5.06
-169.21
2007
-119.96
-195.35
-106.36
-0.0758
-421.75
2006
-131.75
-106.25
-88.76
-0.15
-326.91
2005
-139.92
-925.67
-114.13
-0.12
-1179.84
2004
-117.83
-90.61
-229.7
-175.34
-613.48
2003
-91.69
-93.46
-391.65
-162.39
-739.19
2002
-519.63
7.58
-485.44
-80.55
-1078.04
2001
3675.17
-4183.69
-1436.64
-470.57
-2415.73
2000
-3655.81
-7281.5
-2245.79
-794.01
-13977.11
1999
-2727.27
-1775.15
-882.35
-1591.51
-6976.28
1998
-5306.12
3584.23
-3773.58
-4062.5
-9557.97
1997
-4347.83
-8372.09
-4651.16
-6122.45
-23493.53
1996
-4232.8
-4232.8
-5314.01
-4830.92
-18610.53
Brief information
TG Therapeutics, Inc. (TGTX) stock split history
Understanding the historical stock splits of TG Therapeutics, Inc. (TGTX) provides insights into its past financial decisions and investor sentiment. A stock split occurs when a company increases its share count by dividing its existing shares. The most recent split took place on April 30, 2012 with a ratio of 100:5625. Throughout its history, the company has undergone 2 stock splits. Below, we delve deeper into this history, highlighting past financial strategies.
